Philippe Savard is a Senior Principal at Sagard and joined the firm in 2023. As a member of Sagard Healthcare Partners, Philippe invests in approved and commercialized biopharmaceuticals, diagnostics, and medical devices that are protected by strong intellectual property. He is responsible for all aspects of the investment process, including origination, due diligence, execution, and portfolio management. He has over a decade of experience in healthcare and is based in Toronto, Canada.
Prior to Sagard, Philippe was Senior Vice-President, General Counsel & Corporate Secretary for Acerus Pharmaceuticals, a Canadian public specialty pharma company, where he was involved in all aspect of the pharma operations. Prior to Acerus, Philippe worked at DRI Capital as a Director, where he was responsible for making royalty investments in the biopharmaceutical industry. Prior to DRI Capital, Philippe was an associate at both Paul, Weiss and Ropes & Gray, where his practice focused on private equity, M&A and capital markets transactions.
Philippe holds both a J.D. and an MBA from the University of Toronto. He also holds both a Master of Science and Bachelor of Science (Honours) in microbiology and immunology from McGill University. Philippe is called to the bar in Ontario, New York, and Massachusetts.
